Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841205 | 1.00 | PLAU (0.55) | PLAUDRD2DRD3ADRA1AOPRK1 | |
| Hydrochloric Acid SCHEMBL7239629 | 0.98 | PLAU (0.53) | PLAUDRD2DRD3ADRA1AOPRK1 | |
| Hydrochloric Acid SCHEMBL7239634 | 0.98 | PLAU (0.53) | PLAUDRD2DRD3ADRA1AOPRK1 | |
| Hydrochloric Acid SCHEMBL5197466 | 0.84 | DRD2 (0.62) | PLAUDRD2DRD3ADRA1AOPRK1 | |
| SCHEMBL31324610 | 0.82 | DRD2 (0.46) | PLAUDRD2DRD3ADRA1A | |
| SCHEMBL11444214 | 0.82 | DRD2 (0.46) | PLAUDRD2DRD3ADRA1A | |
| SCHEMBL23045125 | 0.78 | CHRM3 (0.42) | — | |
| SCHEMBL14591309 | 0.78 | PLAU (0.55) | PLAUDRD2DRD3ADRA1A | |
| SCHEMBL22061859 | 0.78 | DRD2 (0.74) | PLAUDRD2DRD3ADRA1A | |
| SCHEMBL3760340 | 0.78 | PLAU (0.55) | PLAUDRD2DRD3ADRA1AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4244050-A | — | — | None | — | — | JP | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1051990-C | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes and 3-aminochromones | LILLY CO ELI (US) | 2000-05-03 | — | — | CN | disclosed |
| CN-1039967-C | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes, and 3-aminothiochromanes | LILLY CO ELI (US) | 1998-09-30 | — | — | CN | disclosed |
| US-5637624-A | ANTISEROTONIN AGENT | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0498590-B1 | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes | LILLY CO ELI (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0471515-B1 | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes | LILLY CO ELI (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0498590-A1 | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes | ELI LILLY AND COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| CN-1059903-A | Nuclear substituted 2-amino-1,2,3,4 ,-tetraline, the amino thiochroman of the amino dihydrobenzopyrans 3-of 3- | LILLY CO ELI (US) | 1992-04-01 | — | — | CN | disclosed |
| US-5096908-A | 5-HT1A agonist | ELI LILLY AND COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0471515-A1 | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes | ELI LILLY AND COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0451008-A1 | 8-Sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| CN-1055179-A | Novel 8-sulphonamide methylene radical-2-amino-1,2,3,4-tetralin | MERRELL DOW PHARMA (US) | 1991-10-09 | — | — | CN | disclosed |
| EP-0447727-A1 | Novel 8-sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0385658-A1 | Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes | ELI LILLY AND COMPANY (US) | 1990-09-05 | — | — | EP | disclosed |
| CN-1045099-A | Ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes | LILLY CO ELI (US) | 1990-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | PLAU 3800/4885DRD2 272/4885DRD3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.